Meitheal Patent-Cliff Exposure & CMS Drug Spending Portfolio
Meitheal (US): 5 reconciled FDA prescription therapies, $118K 2024 CMS Part D & Medicaid spend, and $2,193 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 5 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2039-01-01 |
| 2024 CMS Total Public Spend | $118K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $118K |
| California HCAI SB 17 Filings | Specialty launch notice ($2,193 intro WAC) |